Respiratory syncytial virus (RSV) is a leading cause of pneumonia and hospitalizations in children and older adults. A search for a vaccine may finally be over. Join host, Geoff Wall, and guest, Jake Galdo, as they dive into part 1 of a two-part series examining new research on the proposed RSV vaccine.

The GameChanger
RSV, COVID-19, and influenza are major disease burdens on children and older adults. Fortunately, COVID-19 and influenza have widely available vaccines – and maybe soon for RSV. A recent study of the mRNA vaccine in older adults improves antibody titers.

Show Segments
00:00 - Introductions
03:06 - Barriers to Development of the RSV Vaccine
06:46 - Looking at the RSV Vaccine Study
13:01 - The GameChanger: The Vaccine Outcomes
20:57 - Connecting to Practice: The Potential Future of This Vaccine
28:19 - Closing Remarks

Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest
Jake Galdo, PharmD, MBA, BCPS, BCGP
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad

References and Resources
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951. PMID: 15858184.


Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe barriers to development of an RSV vaccine
2. Discuss outcomes of an RSV vaccines in older adults

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-192-H06-P
Initial release date: 05/01/2023
Expiration date: 05/01/2024

Follow CEimpact on Social Media:
LinkedIn
Instagram